European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
CINCINNATI ( WXIX /Gray News) - A 7-year-old is in a hospital in Ohio fighting for her life after experiencing her second ...
For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...
Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...
In addition to improving heart failure symptoms, finerenone reduced the onset of new type 2 diabetes in patients with mildly ...
If you’ve experienced a heart attack, your healthcare provider may prescribe certain medications to help prevent one from ...
Early identification of kidney dysfunction in patients with advanced heart failure is crucial for timely interventions. In ...
The kidney health benefits of SGLT2 inhibitors extend to patient subgroups with chronic kidney disease (CKD) in combo with other conditions.
Astellas Pharma announces US FDA listing of DIGITIVA for the management of heart failure: Tokyo Friday, September 20, 2024, 11:00 Hrs [IST] Astellas Pharma Inc. announced that DIG ...
Heart failure arises when the heart cannot pump blood efficiently, leading to symptoms such as shortness of breath and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback